Patents Represented by Attorney, Agent or Law Firm J. Michael Dixon
  • Patent number: 6831088
    Abstract: Compounds of formula (1): and their salts, solvates, prodrugs, etc., wherein the substituents have the values mentioned herein, are Procollagen C-Proteinase (PCP) inhibitors and have utility in conditions mediated by PCP.
    Type: Grant
    Filed: August 19, 2003
    Date of Patent: December 14, 2004
    Assignee: Pfizer Inc.
    Inventors: Paul Vincent Fish, Jackie Diane Kendall, Gavin Alistair Whitlock
  • Patent number: 6828460
    Abstract: The present invention relates to the use of certain resorcinol derivatives as skin lightening agents.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: December 7, 2004
    Assignee: Pfizer Inc.
    Inventors: Andrew Francis Browning, Eric William Collington, Martin James Procter, Joanna Victoria Geden
  • Patent number: 6821972
    Abstract: Compounds of formula (I): and their salts, solvates, hydrates and prodrugs are useful PCP inhibitors, processes for making the same, compositions comprising the same, and methods of treating a PCP-mediated condition or disease using the same.
    Type: Grant
    Filed: March 29, 2002
    Date of Patent: November 23, 2004
    Assignee: Pfizer Inc.
    Inventors: Simon Bailey, Paul Vincent Fish, Kim James, Gavin Alistar Whitlock
  • Patent number: 6787652
    Abstract: The present invention provides novel compounds of the Formula I and prodrugs thereof, geometric and optical isomers thereof, and pharmaceutically acceptable salts of such compounds, prodrugs and isomers, wherein R1 to R8 and W are as described herein. Pharmaceutical compositions containing such compounds, prodrugs, isomers or pharmaceutically acceptable salts thereof, and methods, pharmaceutical compositions and kits for treating obesity, overweight condition, hyperlipidemia, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression, osteoporosis, cardiac arrhythmias, glaucoma and congestive heart failure are also provided.
    Type: Grant
    Filed: September 27, 2000
    Date of Patent: September 7, 2004
    Assignee: Pfizer, Inc.
    Inventors: Robert L. Dow, Yuan-Ching P. Chiang, Kimberly G. Estep
  • Patent number: 6750363
    Abstract: An efficient and selective process, capable of scale-up, to make itaconate derivatives of formula (IV), and/or succinate derivatives of formula (V) and/or (VI) by asymmetric hydrogenation of the itaconate derivatives. wherein R, R1 and R2 are as defined herein.
    Type: Grant
    Filed: July 18, 2002
    Date of Patent: June 15, 2004
    Assignee: Pfizer, Inc.
    Inventors: Andrew Michael Derrick, Nicholas Murray Thomson
  • Patent number: 6730703
    Abstract: The present invention provides a method of treating sebaceous gland disorders comprising administering to a patient in need of said treatment an effective amount of a compound named [(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diiso-propyl-phenyl ester or a pharmaceutically acceptable salt thereof. Particularly, methods of treating sebaceous gland disorders are provided wherein said disorders are selected from seborrhea, acnes, perioral dermatitis, rosacea, and corticosteroid-induced acneiform lesions. The present invention provides methods of treating acnes such as, for example, chloracne, ciliaris acne, cystic acne, keratosa acne, vulgaris acne, senile acne, and medicinal acne.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: May 4, 2004
    Assignee: Warner-Lambert Company
    Inventor: Reynold Homan
  • Patent number: 6723744
    Abstract: A compound of the formula wherein W, R1, R2, R3, R4, R5, R6, R7, R8 and R13 are as defined herein, useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesteremia, depression, osteoporosis and hair loss.
    Type: Grant
    Filed: September 24, 2002
    Date of Patent: April 20, 2004
    Assignee: Pfizer, Inc.
    Inventors: Gary E. Aspnes, Yuan-Ching P. Chiang
  • Patent number: 6716861
    Abstract: Compounds of formula (I): wherein the substituents are as defined herein, and their salt, solvates, and prodrugs are procollagen C-proteinase (PCP) inhibitors useful in treating conditions mediated by PCP.
    Type: Grant
    Filed: December 12, 2001
    Date of Patent: April 6, 2004
    Assignee: Pfizer, Inc.
    Inventors: Usa Datta, Paul Vincent Fish, Kim James, Gavin Alistair Whitlock
  • Patent number: 6664291
    Abstract: The present invention relates to novel thyroid receptor ligands and, more particularly, relates to malonamic acids and derivatives thereof of Formula I, which are useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesteremia, depression, osteoporosis and hair loss. The present invention also provides methods, pharmaceutical compositions and kits for treating such diseases and disorders.
    Type: Grant
    Filed: March 28, 2001
    Date of Patent: December 16, 2003
    Assignee: Pfizer, Inc.
    Inventors: Yuan-Ching P. Chiang, Gary E. Aspnes, Kimberly G. Estep
  • Patent number: 6590105
    Abstract: The present invention relates to certain resorcinol derivatives and their use as skin lightening agents.
    Type: Grant
    Filed: September 7, 2001
    Date of Patent: July 8, 2003
    Assignee: Warner-Lambert Company
    Inventors: Stuart E. Bradley, Eric W. Collington, Matthew C. Fyfe, Martin J. Procter, Colin P. Sambrook Smith
  • Patent number: 6504037
    Abstract: The present invention relates to an improved process for preparing 4-substituted resorcinol derivatives, and intermediate compounds useful in the preparation of such resorcinol derivatives.
    Type: Grant
    Filed: March 8, 2001
    Date of Patent: January 7, 2003
    Assignee: Warner-Lambert Company
    Inventors: Stuart Edward Bradley, John Kitchin, Graham Michael Wynne
  • Patent number: 6475539
    Abstract: This invention is directed to a low pH nutritional formula that contains high levels of macronutrients, vitamins and minerals. The pH of the enteral formula is from about 3.0-4.6 and delivers at least 25% of the RDI for selected vitamins and minerals in a 237 ml. serving. The enteral formula uses a stabilizing system comprising high methoxy pectin to stabilize the protein and a unique process to produce the formula.
    Type: Grant
    Filed: April 16, 1999
    Date of Patent: November 5, 2002
    Assignee: Abbott Laboratories
    Inventors: Normanella T. DeWille, Jeffrey G. Morris, Terrence B. Mazer, Paul S. Anloague, Amanda L. Smeller, Michael A. Chandler, Diane M. Garcia, Louis I. Ndife
  • Patent number: 6468987
    Abstract: An enteral nutritional product for a person having ulcerative colitis contains in combination (a) an oil blend which contains eicosapentaenoic acid (20:5n3) and/or docosahexaenoic acid (22:6n3), and (b) a source of indigestible carbohydrate which is metabolized to short chain fatty acids by microorganisms present in the human colon. Preferably the nutritional product also contains one or more nutrients which act as antioxidants.
    Type: Grant
    Filed: September 14, 1999
    Date of Patent: October 22, 2002
    Assignee: Abbott Laboratories
    Inventors: Stephen Joseph Demichele, Keith Allen Garleb, John William McEwen, Martha Kay Fuller
  • Patent number: 6447797
    Abstract: It has been discovered that certain phosphoinositides demonstrate antibacterial activity. Particularly, these phosphoinositides have been discovered to prevent the adhesion of H. influenzae onto the nasopharyngeal cells of mammals, and, in particular, humans. Phosphoinositides useful with the present invention have the following formula: wherein R1 and R2 are selected from the group consisting of hydrogen and monounsaturated and saturated fatty acids having a carbon chain length of C6 to C20 and R1 and R2 can be the same or different; and R3 to R7 are selected from the group consisting of hydrogen or a phosphate moiety with at least two of R3 to R7 being a phosphate moiety; and hydrates and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 19, 2001
    Date of Patent: September 10, 2002
    Assignee: Abbott Laboratories
    Inventors: Shie-Ming Hwang, Yung-Sheng Huang, Jim-Wen Liu, Pradip Mukerji, Steven Neal Anderson, Jonathan A. Meulbroek
  • Patent number: 6444700
    Abstract: In its broadest aspect, the present invention is directed to the discovery of immunonutritional products that are useful in reducing the immunological system suppression that results from stress. The stress may be in the form of physical exertion, mental exhaustion, disease states and the like. In one embodiment, the invention relates to a nutritional composition comprising a structured glyceride component and an antioxidant system. This nutritional composition has been shown to be highly effective in reducing immune system down regulation or dysregulation as a result of stress.
    Type: Grant
    Filed: March 19, 2001
    Date of Patent: September 3, 2002
    Assignee: Abbott Laboratories
    Inventors: Stephen J. DeMichele, John W. McEwen, Steven M. Wood
  • Patent number: 6387883
    Abstract: The present invention relates to methods and nutritional compositions for the prevention and treatment of cachexia and anorexia. The methods of the invention comprise administering a composition comprising effective amounts of &ohgr;-3 fatty acids such as alpha-linolenic acid, stearidonic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid or mixtures thereof; of branched-chain amino acids valine, leucine, isoleucine or mixtures thereof; with or without reduced levels of tryptophan and 5-hydroxytryptophan; and of antioxidant system selected from the group comprising beta-carotene, vitamin C, vitamin E, selenium, or mixtures thereof.
    Type: Grant
    Filed: August 18, 2000
    Date of Patent: May 14, 2002
    Assignee: Abbott Laboratories
    Inventors: Bonnie Chandler Abbruzzese, Mark Anthony McCamish, Frederick Oliver Cope, Stephen Joseph DeMichele
  • Patent number: 6365597
    Abstract: The invention related to 4-aza-17&bgr;-(cyclopropoxy)-androst-5&agr;-androstan-3-one, 4-aza-17&bgr;-(cyclopropylamino)-androst-4-en-3-one and related compounds and to compositions incorporating these compounds, as well as the inhibition of C17-20 lyase, 5&agr;-reductase and C17&agr;-hydroxylase and to the use of these compounds in the treatment of androgen and estrogen mediated disorders, including benign prostatic hyperplasia, androgen mediated prostate cancer, estrogen mediated breast cancer and to DHT-mediated disorders such as acne. Disorders relating to the oversynthesis of cortisol, for example, Cushing's Syndrome, are also included. The treatment of androgen-dependent disorders also includes a combination therapy with known androgen-receptor antagonists, such as flutamide.
    Type: Grant
    Filed: February 11, 1997
    Date of Patent: April 2, 2002
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: James R. Pribish, Cynthia A. Gates, Philip M. Weintraub
  • Patent number: 6365218
    Abstract: The present invention provides an improved pediatric formula and methods for providing nutrition to and enhancing tolerance in pediatric patients. The formula may be provided in powder, concentrate or ready-to-feed forms. The pediatric formula comprises, based on a 100 kcal basis, about 8 to about 16 grams carbohydrate (preferably about 9.4 to about 12.3 grams), about 3 to about 6 grams lipid (preferably about 4.7 to about 5.6 grams), about 1.8 to about 3.3 grams protein (preferably about 2.4 to about 3.3 grams), and a tolerance improver comprising about 37 to about 370 milligrams (preferably about 74 to about 222 milligrams, more preferably about 111 to about 148 milligrams) xanthan gum.
    Type: Grant
    Filed: February 4, 2000
    Date of Patent: April 2, 2002
    Assignee: Abbott Laboratories
    Inventors: Marlene W. Borschel, Steven T. Luebbers, Cynthia J. Black, Daniel L. McKamy, Timothy Costigan
  • Patent number: 6326355
    Abstract: The present invention relates to methods and nutritional compositions for the prevention and treatment of cachexia and anorexia. The methods of the invention comprise administering a composition comprising effective amounts of &ohgr;-3 fatty acids such as alpha-linolenic acid, stearidonic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid or mixtures thereof, of branched-chain amino acids valine, leucine, isoleucine or mixtures thereof; with or without reduced levels of tryptophan and 5-hydroxytryptophan; and of antioxidant system selected from the group comprising beta-carotene, vitamin C, vitamin E, selenium, or mixtures thereof.
    Type: Grant
    Filed: January 7, 2000
    Date of Patent: December 4, 2001
    Assignee: Abbott Laboratories
    Inventors: Bonnie Chandler Abbruzzese, Mark Anthony McCamish, Frederick Oliver Cope, Stephen Joseph Demichele
  • Patent number: 6313273
    Abstract: A high quality soy protein concentrate (SPC) was produced by a process of enzyme treatment combined with ultrafiltration. Soy flour, the starting material, was enzymatically treated with commercial pectinases and diafiltered with a porous stainless steel ultrafiltration system. The resulting product had reduced levels of physic acid and nucleic acids due to contaminant phytase and nuclease activity in the pectinase enzymes. The functionality of the SPC was improved due to increased solubility compared to conventional soy isolates produced by acid precipitation. High performance liquid chromatography gel filtration profiles indicated that the proteins in the SPC remained intact. The SPC also had reduced flavor when compared to the original soy flour according to gas chromatography flavor profiles and sensory evaluation.
    Type: Grant
    Filed: August 25, 1999
    Date of Patent: November 6, 2001
    Assignee: Abbott Laboratories
    Inventors: Ronald L. Thomas, Louis I. Ndife, Hilary Shallo, Lynn P. Nelles